Implementation of Cancer Plans in the United States: A Review
Abstract
:1. Introduction
2. Methods
3. Results
4. Discussion
4.1. Common Elements among the Implementation Plans
4.2. Unique Examples of Implementation
4.3. Measuring Progress of Implementation
4.4. Synergies in Implementation
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Appendix A. Florida Cancer Plan 2020–2025 Implementation Plan
- Coordinated and collaborative
- Non-duplicative
- Leveraging the strengths of individuals and organizations involved in cancer control efforts
- Addressing gaps in efforts
- Measurable and progress is tracked
- Utilizing existing, in-kind, and new resources
- Importance:
- ⚬
- Is it important that Floridians achieve this objective over the next 1–2 years?
- ⚬
- Is the objective a sentinel or bellwether for change?
- Effectiveness:
- ⚬
- Is this objective the most useful effort we can make to achieve the goal?
- ⚬
- Will achieving this objective lead to a meaningful impact on Florida’s cancer burden?
- Measurable:
- ⚬
- Are reliable data available now or could data be developed to measure outcomes?
- Equitable:
- ⚬
- If the objective is met, to what degree would all Floridians benefit?
- Synergistic:
- ⚬
- Are stakeholders willing to work on this objective?
- Evidence-Based:
- ⚬
- Is the strategy based on research or proven best practices, thus increasing the likelihood that the strategy will be successful? (Note: The strategies in the Plan should be evidence-based, as this criterion was used for inclusion; however, it is good to re-examine the strategy to ensure it is the best approach, given available evidence.)
- Feasibility:
- ⚬
- Is it feasible to execute the strategy over the next 1–2 years, considering the costs associated, resources required, cultural appropriateness, political will, likelihood of stakeholders working cooperatively, etc.?
- Synergistic:
- ⚬
- Is this strategy one we need to accomplish together, rather than one stakeholder bearing sole responsibility?
- ⚬
- Are stakeholders willing to work on this strategy?
- Priority objective and measures (from the Florida Cancer Plan)
- Priority strategies chosen to achieve the objective (from the Florida Cancer Plan)
- Tasks or activities to achieve the strategies with relevant timeframes for completion and who is responsible
- Short- and/or intermediate-term outcomes with measures to gauge progress on achieving strategies (if needed)
- Resources and information needed to achieve strategies (funding, in-kind)
- Stakeholders to engage (who are the key stakeholders to engage and how will we do that, etc.)
- Communication processes (who do we need to communicate with about the strategy and when, etc.)
- Progress notes section
- Increase the number and diversity of Floridians engaged in the Regional Cancer Collaborative activities.
- ⚬
- Encourage Floridians interested in joining the fight against cancer to contact their local Regional Cancer Collaborative.
- ⚬
- Highlight the work of the Collaboratives on the CCRAB website and in progress reports and other communications.
- Encourage Regional Cancer Collaborative members and stakeholders to use the Florida Cancer Plan for planning, funding, and advocacy.
- ⚬
- Meet with the leaders of the six Regional Cancer Collaboratives on an annual basis to get their input on priority objectives, share progress on priorities, identify gaps/opportunities to work together on, and to strategize about coordinated efforts.
- ⚬
- Disseminate priority objective information to Collaboratives so they can work to align their regional efforts with statewide efforts.
- ⚬
- Communicate overall plan successes, progress, and areas of continued need among Collaboratives periodically (e.g., quarterly) throughout the year.
- ⚬
- Create a CCRAB speakers list of members willing to attend regional Collaborative meetings to share CCRAB information/updates and hear about Collaborative efforts.
- Coordinate with Regional Cancer Collaboratives to use consistent and accurate cancer control messages.
- ⚬
- Work with the FL DOH and Collaboratives to identify cancer control messages that are/will be associated with priority objectives identified from the plan. For each priority objective, identify possible public and provider education and advocacy messages that can be shared with the Collaboratives.
- ⚬
- Provide written materials/messages to Collaboratives that they may disseminate and adapt for use in their own regions.
- Work with the Regional Cancer Collaboratives to identify two areas for focused collaborative efforts over the 5-year plan period
- ⚬
- Conduct an initial meeting with the FL DOH and leadership of the six Collaboratives to identify potential areas of collaborative focus for the 5-year plan period (Note: Feedback gathered during the six regional Town Hall meetings in 2019 indicated that the following may be areas of interest: transportation, lung cancer screening, and HPV vaccination).
- ⚬
- Use input on areas of interest from Collaboratives to help guide selection of priority objectives from the cancer plan for the first 1–2 years of implementation.
- ⚬
- During subsequent annual meetings with Collaborative leadership, set aside time to review progress and adjust strategies for the focused collaborative efforts.
- ⚬
- Communicate with Collaboratives on a regular (e.g., quarterly) basis to coordinate campaign efforts, via email and/or conference call.
- Each priority objective selected from the Florida Cancer Plan has measures associated with it. CCRAB should collect and report on those measures to gauge progress. Additional short- or intermediate-term outcomes may need to be identified to gauge progress for each priority objective.
- Tracking and sharing progress on the statewide collaboration among CCRAB, Regional Cancer Collaboratives, and other state cancer control stakeholders is also important. For each Action Plan, metrics for collaboration should be included to convey what can be achieved by working together. For example, under an objective to increase the proportion of limited stage (Stage 1 and 2) lung cancer and decrease late-stage (Stage 3 and 4) lung cancer in Florida, strategies may include increasing awareness, access, and usage of lung cancer screening in target populations. Metrics for collaboration may include tracking the amount of time between action steps, diversity of resources used, and/or comparing the individual stakeholder’s projected value in the effort (number of lung cancer patients diagnosed with limited stage cancer versus late-stage cancer) versus the collaboration’s realized value of the effort demonstrating synergy.
- Reporting on all Florida Cancer Plan goals and associated objectives/measures should be included in the state statute-mandated annual report from CCRAB to the Florida Governor and Florida Legislature (s. 1004.435, section 4(p)), with special focus on Plan priority goals and objectives.
- A Florida Cancer Plan 2020-2025 dashboard may be an effective way to communicate progress. A dashboard that includes all plan objectives/measures with a special focus on the priority objectives chosen from the Florida Cancer Plan may be the most effective way to communicate progress, to call attention to successes, and indicate if more collaborative action is needed to achieve intended outcomes).
- CCRAB’s annual reports could include easy-to-understand graphical depictions of overall progress on priority objectives, including what CCRAB, the FL DOH, the Regional Cancer Collaboratives and other key stakeholders are doing/were able to achieve together.
- Annual progress summaries (1–2 pagers with easy to understand graphics) on each priority objective would be good resources to share with Regional Cancer Collaboratives and other stakeholders, to convey successes and outline additional resources/collaborative efforts needed to achieve objectives.
- Finalize this implementation plan with input from the FL DOH and Regional Collaborative staff and leadership and CCRAB members
- Select priority objectives from the plan using the criteria outlined above (if possible, Regional Collaborative staff and leaders should attend this meeting, to provide input on selecting strategies)
- Identify a process and timeframe for CCRAB to select strategies within the priority objective and complete an action plan
- Discuss next steps for Collaboratives, including development of action plans for their region
- Identify key stakeholder communication strategies and timeframes, e.g., how and how often to communicate with Regional Collaboratives on plan implementation
- Finalize and disseminate CCRAB priority objective action plans to CCRAB members and other stakeholders, as appropriate
- Regional Collaboratives will hold meetings to select strategies for the agreed upon priority objectives, that leverage existing strengths, programs, efforts within their region, and identify regional stakeholders to recruit to help with implementation
- Communicate with the FL DOH, Regional Collaboratives and other key stakeholders on a regular basis about Florida Cancer Plan implementation progress, needs and next steps (e.g., monthly calls with Collaborative staff and leadership, periodic priority objective updates to all CCRAB members and other stakeholders)
- Establish a timeframe for systematically reviewing progress on the priority objectives (every 1-2 years) and selecting to continue and/or identify new 1-2 year priorities from the Plan
Priority objective and measures (from the Florida Cancer Plan) | ||||||||
Priority Strategies Chosen to Achieve the Objective (from the Cancer Plan) | Tasks to Achieve the Strategy | Timeframe for Completion | Person, Organization Responsible | Short- and Intermediate-Term Outcomes, Measures | Resources, Information Needed | Stakeholders to Engage | Communication Processes | Progress Notes |
Strategy 1 | Task 1 Task 2 Task 3 | |||||||
Strategy 2 | Task 1 Task 2 Task 3 |
Appendix B. PRISMA Checklist
Section/Topic | # | Checklist Item | Reported on Page # |
TITLE | |||
Title | 1 | Identify the report as a systematic review, meta-analysis, or both. | 1 |
ABSTRACT | |||
Structured summary | 2 | Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. | 1 |
INTRODUCTION | |||
Rationale | 3 | Describe the rationale for the review in the context of what is already known. | 1–2 |
Objectives | 4 | Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). | 1–2 |
METHODS | |||
Protocol and registration | 5 | Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. | 2–3 |
Eligibility criteria | 6 | Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. | 2–3 |
Information sources | 7 | Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. | 2–3 |
Search | 8 | Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. | 2–3, |
Study selection | 9 | State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). | 2–3 |
Data collection process | 10 | Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. | 2–3 |
Data items | 11 | List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. | 2–3 |
Risk of bias in individual studies | 12 | Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. | 2–3 |
Summary measures | 13 | State the principal summary measures (e.g., risk ratio, difference in means). | 2–3 |
Synthesis of results | 14 | Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. | 2–3 |
Risk of bias across studies | 15 | Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). | 2–3 |
Additional analyses | 16 | Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. | 2–3 |
RESULTS | |||
Study selection | 17 | Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. | 3–5 |
Study characteristics | 18 | For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. | 3–5 |
Risk of bias within studies | 19 | Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). | 3–5 |
Results of individual studies | 20 | For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. | 3–5 |
Synthesis of results | 21 | Present results of each meta-analysis done, including confidence intervals and measures of consistency. | 3–5 |
Risk of bias across studies | 22 | Present results of any assessment of risk of bias across studies (see Item 15). | 3–5 |
Additional analysis | 23 | Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]). | N/A |
DISCUSSION | |||
Summary of evidence | 24 | Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). | 5–9 |
Limitations | 25 | Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). | 5–9 |
Conclusions | 26 | Provide a general interpretation of the results in the context of other evidence, and implications for future research. | 9–10 |
FUNDING | |||
Funding | 27 | Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. | 10 |
References
- Hohman, K.; Given, L.; Graaf, L.; Sergeant, J.; Muthukuda, D.; Devery, T.; Jones, K.; Sittig, K.W. Evolution of comprehensive cancer control plans and partnerships. Cancer Causes Control 2018, 29, 1181–1193. [Google Scholar] [CrossRef] [PubMed]
- Hayes, N.S.; Hohman, K.; Vinson, C.; Pratt-Chapman, M. Comprehensive cancer control in the U.S.: Summarizing twenty years of progress and looking ahead. Cancer Causes Control 2018, 29, 1305–1309. [Google Scholar] [CrossRef] [PubMed]
- Given, L.S.; Coughlin, R.; Hager, P.; Lopez, K.; Merriam, G.; Morwood, K.; Nelson, D.; Crawford, A. Comprehensive cancer control in the US: 20 years of progress. Cancer Causes Control 2018, 29, 1151–1161. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Vinson, C.A.; Staples, C.; Shafir, S.; Given, L.; Miller, N. Collaborating to conquer cancer: The role of partnerships in comprehensive cancer control. Cancer Causes Control 2018, 29, 1173–1180. [Google Scholar] [CrossRef] [PubMed]
- Given, L.S.; Hohman, K.; Kostelecky, B.; Vinson, C. Cancer control planning: Self-assessment for pre-planning, development, implementation and evaluation of national cancer control plans. Cancer Causes Control 2018, 29, 1297–1303. [Google Scholar] [CrossRef] [PubMed]
- Parkin, D.M. The role of cancer registries in cancer control. Int. J. Clin. Oncol. 2008, 13, 102–111. [Google Scholar] [CrossRef] [PubMed]
- Given, L.S.; Hohman, K.; La Porta, M.; Belle-Isle, L.; Rochester, P. Comprehensive cancer control in the United States: Progress and opportunity. Cancer Causes Control. 2010, 21, 1965. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- White, M.C.; Babcock, F.; Hayes, N.S.; Mariotto, A.B.; Wong, F.L.; Kohler, B.A.; Weir, H.K. The history and use of cancer registry data by public health cancer control programs in the United States. Cancer 2017, 123, 4969–4976. [Google Scholar] [CrossRef] [PubMed]
- Khan, K.; Curtis, C.R.; Ekwueme, D.U.; Stokley, S.; Walker, C.; Roland, K.; Saraiya, M. Preventing cervical cancer: Overviews of the National Breast and Cervical Cancer Early Detection Program and 2 US immunization programs. Cancer 2008, 113, 3004–3012. [Google Scholar] [CrossRef] [PubMed]
- Major, A.; Stewart, S.L. Celebrating 10 years of the national comprehensive cancer control program, 1998 to 2008. Prev. Chronic Dis. 2009, 6, A113. [Google Scholar]
- Pyron, T.; Fonseka, J.; Young, M.; Zimmerman, L.; Moore, A.R.; Hayes, N. Examining comprehensive cancer control partnerships, plans, and program interventions: Successes and lessons learned from a utilization-focused evaluation. Cancer Causes Control. 2018, 29, 1163–1171. [Google Scholar] [CrossRef] [PubMed]
- The Florida Cancer Plan 2020–2025. Available online: http://www.ccrab.org/cancer-plan (accessed on 25 August 2020).
- Stewart, L.A.; Clarke, M.; Rovers, M.M.; Riley, R.D.; Simmonds, M.; Stewart, G.B.; Tierney, J.F.; PRISMA-IPD Development Group. Preferred Reporting Items for a Systematic Review and Meta-analysis of Individual Participant Data. JAMA 2015, 313, 1657–1665. [Google Scholar] [CrossRef] [PubMed]
- Momin, B.; Millman, A.J.; Nielsen, D.B.; Revels, M.; Steele, C.B. Promising practices for the prevention of liver cancer: A review of the literature and cancer plan activities in the National Comprehensive Cancer Control Program. Cancer Causes Control. 2018, 29, 1265–1275. [Google Scholar] [CrossRef] [PubMed]
- Pollack, L.A.; Greer, G.E.; Rowland, J.H.; Miller, A.; Doneski, D.; Coughlin, S.S.; Stovall, E.; Ulman, D. Cancer Survivorship: A New Challenge in Comprehensive Cancer Control. Cancer Causes Control 2005, 16, 51–59. [Google Scholar] [CrossRef] [PubMed]
- Underwood, J.M.; Lakhani, N.; Rohan, E.; Moore, A.; Stewart, S.L. An evaluation of cancer survivorship activities across national comprehensive cancer control programs. J. Cancer Surviv. 2015, 9, 554–559. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pennsylvania Comprehensive Cancer Control Plan. 2019. Available online: https://www.health.pa.gov/topics/Documents/Diseases%20and%20Conditions/Cancer/2019-2023%20Pennsylvania%20Cancer%20Control%20Plan.pdf (accessed on 28 January 2021).
- Delaware Cancer Consortium: The Next Five-Year Plan, 2017–2021. 2017. Available online: https://ftp.cdc.gov/pub/Publications/Cancer/ccc/delaware_ccc_plan-508.pdf (accessed on 28 January 2021).
- New Mexico Cancer Plan. 2020. Available online: https://ftp.cdc.gov/pub/Publications/Cancer/ccc/new-mexico-ccc-plan-508.pdf (accessed on 28 January 2021).
- Montana Comprehensive Cancer Control Plan. 2016. Available online: https://ftp.cdc.gov/pub/Publications/Cancer/ccc/montana_ccc_plan.pdf (accessed on 28 January 2021).
- Melkonian, S.C.; Jim, M.A.; Haverkamp, D.; Wiggins, C.L.; Mccollum, J.; White, M.C.; Kaur, J.S.; Espey, D.K. Disparities in Cancer Incidence and Trends among American Indians and Alaska Natives in the United States, 2010–2015. Cancer Epidemiol. Biomark. Prev. 2019, 28, 1604–1611. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Torre, L.A.; Sauer, A.M.G.; Chen, M.S., Jr.; Kagawa-Singer, M.; Jemal, A.; Siegel, R.L. Cancer statistics for Asian Americans, Native Hawaiians, and Pacific Islanders, 2016: Converging incidence in males and females. CA A Cancer J. Clin. 2016, 66, 182–202. [Google Scholar] [CrossRef] [PubMed]
- Pacific Regional Comprehensive Cancer Control Plan. 2007. Available online: https://ftp.cdc.gov/pub/Publications/Cancer/ccc/pacific_regional_ccc_plan_2007_2012.pdf (accessed on 28 January 2021).
- 2018–2023 New York State Comprehensive Cancer Control Plan Dashboard. Available online: https://webbi1.health.ny.gov/SASStoredProcess/guest?_program=/EBI/PHIG/apps/cancer_dashboard/cd_dashboard&p=sh (accessed on 28 January 2021).
- Love, B.; Benedict, C.; Villalobos, A.V.K.; Cone, J.N. Communication and comprehensive cancer control coalitions: Lessons from two decades of campaigns, outreach, and training. Cancer Causes Control 2018, 29, 1239–1247. [Google Scholar] [CrossRef] [PubMed]
State or Territory | Is the Cancer Plan Current to 2020/2021? | Engagement: Existence of Task Forces and/or Workgroups | Existence of Regional Coalitions | Grant Applications on Website |
---|---|---|---|---|
Alabama | X | X | ||
Alaska | X | X | ||
Arizona | ||||
Arkansas | X | X | ||
California | ||||
Colorado | X | X | X | |
Connecticut | X | |||
Delaware | X | X | ||
Florida | X | X | ||
Georgia | X | |||
Hawaii | X | X | X | |
Idaho | X | X | ||
Illinois | X | |||
Indiana | X | X | X | X |
Iowa | X | X | ||
Kansas | X | X | X | |
Kentucky | X | X | ||
Louisiana | X | X | X | X |
Maine | X | X | X | |
Maryland | X | |||
Massachusetts | X | X | ||
Michigan | X | X | ||
Minnesota | X | X | X | |
Mississippi | X | X | ||
Missouri | X | |||
Montana | X | X | X | |
Nebraska | X | X | ||
Nevada | X | X | ||
New Hampshire | X | X | ||
New Jersey | X | |||
New Mexico | X | |||
New York | X | X | ||
North Carolina | X | X | ||
North Dakota | X | X | X | |
Ohio | X | X | ||
Oklahoma | X | |||
Oregon | ||||
Pennsylvania | X | X | X | |
Rhode Island | X | |||
South Carolina | X | X | X | |
South Dakota | X | X | X | |
Tennessee | X | X | ||
Texas | X | X | ||
Utah | X | X | ||
Vermont | X | X | ||
Virginia | X | X | ||
Washington | X | X | X | |
West Virginia | X | X | X | X |
Wisconsin | X | X | X | |
Wyoming | X | X | ||
Pacific Region | X | X | ||
America Samoa | ||||
Commonwealth of Northern Mariana Islands | ||||
Federated States of Micronesia | X | |||
Guam | X | X | ||
Republic of the Marshall Islands | X | |||
Republic of Palau | X | |||
Puerto Rico | X | |||
Washington DC | X |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Bacchus, M.W.; McKee, B.; Gwede, C.K.; Cogle, C.R. Implementation of Cancer Plans in the United States: A Review. Healthcare 2021, 9, 291. https://doi.org/10.3390/healthcare9030291
Bacchus MW, McKee B, Gwede CK, Cogle CR. Implementation of Cancer Plans in the United States: A Review. Healthcare. 2021; 9(3):291. https://doi.org/10.3390/healthcare9030291
Chicago/Turabian StyleBacchus, Michael W., Bobbie McKee, Clement K. Gwede, and Christopher R. Cogle. 2021. "Implementation of Cancer Plans in the United States: A Review" Healthcare 9, no. 3: 291. https://doi.org/10.3390/healthcare9030291
APA StyleBacchus, M. W., McKee, B., Gwede, C. K., & Cogle, C. R. (2021). Implementation of Cancer Plans in the United States: A Review. Healthcare, 9(3), 291. https://doi.org/10.3390/healthcare9030291